Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Accenture
Farmers Insurance
US Department of Justice
Citi
Deloitte
QuintilesIMS
US Army

Generated: August 21, 2018

DrugPatentWatch Database Preview

DIFFERIN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Differin, and what generic alternatives are available?

Differin is a drug marketed by Galderma Labs Lp and is included in five NDAs. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-five patent family members in twenty-two countries.

The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the adapalene profile page.

Drug patent expirations by year for DIFFERIN
Pharmacology for DIFFERIN
Ingredient-typeRetinoids
Drug ClassRetinoid
Medical Subject Heading (MeSH) Categories for DIFFERIN
Synonyms for DIFFERIN
(non-d)Adapalene-d15
106685-40-9
1L4806J2QF
2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo(3.3.1.1(sup 3,7))dec-1-ylphenyl)-
2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-
4CA-0111
6-(3-((3r,5r,7r)-adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-Adamantan-1-yl-4-methoxy-phenyl)-naphthalene-2-carboxylic acid
6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid
6-(4-Methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid
6-[3-(1-adamantyl)-4-methoxy-phenyl]naphthalene-2-carboxylic acid
6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHALENE CARBOXYLIC ACID
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalene-carboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid
6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[4-methoxy-3-(tricyclo[3.3.1.1~3,7~]dec-1-yl)phenyl]naphthalene-2-carboxylic acid
6-[4-methoxy-3-(tricyclo[3.3.1.13,7]dec-1-yl)phenyl]naphthalene-2-carboxylic acid
685A409
A801483
AB0013899
AB01274764_03
AB01274764_04
AB01274764-01
AB01274764-02
AB13763
AB2000023
ABP000590
AC-1974
AC1L1SOH
AC1Q5USH
Adaferin
Adaferin (TN)
Adapalen
ADAPALENE
Adapalene (JAN/USAN/INN)
Adapalene [USAN:BAN:INN]
Adapalene [USAN:INN:BAN]
Adapalene for peak identification, European Pharmacopoeia (EP) Reference Standard
Adapalene, >=98% (HPLC)
Adapalene, European Pharmacopoeia (EP) Reference Standard
Adapalene, pharmaceutical secondary standard; traceable to USP and PhEur
Adapalene, United States Pharmacopeia (USP) Reference Standard
Adapalene/
Adapaleno
Adapaleno [INN-Spanish]
Adapalenum
Adapalenum [INN-Latin]
AJ-45604
AK-72900
AKOS005145841
AKOS015895391
Ambap106685-40-9
AN-593
AOB6389
API0001385
BC205779
BCP9000231
BDBM50048280
BIDD:GT0264
BR-72900
BRD-K33127281-001-01-5
C28H28O3
CAS-106685-40-9
CCG-213060
CCG-221237
CD 271
CD-271
CD271
CHEBI:31174
CHEMBL1265
CHEMBL76401
CPD000466349
CS-1789
CTK8E8906
D01112
D0JC9N
DB00210
Differin (TN)
Differin Gel
Differin Gel 0.1%
Differin, Adapalene
Differin, Teva, Pimpal, Gallet, Adelene, Adeferin
Differine
DR002478
DSSTox_CID_26481
DSSTox_GSID_46481
DSSTox_RID_81652
DTXSID5046481
EBD19549
F2173-0588
FT-0631040
GTPL5429
HMS3264F15
HMS3654F11
HY-B0091
I06-0642
I810
KB-246947
KS-000002B5
KS-1196
LS-172017
LZCDAPDGXCYOEH-UHFFFAOYSA-N
MFCD03106112
MLS000759463
MLS006010036
MolPort-003-986-211
NAP030
NCGC00164617-01
NCGC00164617-02
NCGC00164617-04
NCGC00164617-05
PL029988
PL040836
RTR-001330
S-3513
s1276
SAM001246663
SC-17327
SCHEMBL2747
SMR000466349
SMR002529673
SR-01000942194
SR-01000942194-2
ST2412159
STL453114
TL8000241
Tox21_112236
Tox21_112236_1
TR-001330
UNII-1L4806J2QF
ZINC3784182

US Patents and Regulatory Information for DIFFERIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for DIFFERIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene GEL;TOPICAL 021753-001 Jun 19, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene SOLUTION;TOPICAL 020338-001 May 31, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Galderma Labs Lp DIFFERIN adapalene CREAM;TOPICAL 020748-001 May 26, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for DIFFERIN
Drugname Dosage Strength RLD Date
➤ Subscribe Topical Gel 0.30% ➤ Subscribe ➤ Try a Free Trial

Non-Orange Book US Patents for DIFFERIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,653,140 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders ➤ Try a Free Trial
9,387,187 Administration of 6[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders ➤ Try a Free Trial
8,921,423 Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid ➤ Try a Free Trial
9,872,842 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders ➤ Try a Free Trial
8,729,127 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for DIFFERIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0024 France ➤ Try a Free Trial PRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
C/GB10/005 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Moodys
Baxter
Citi
McKesson
Express Scripts
Teva
Farmers Insurance
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.